- Home
- ANEB vs ENTX Comparison
ANEB vs ENTX Comparison
Compare ANEB & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- ENTX
- Stock Information
- Founded
- ANEB 2020
- ENTX 2010
- Country
- ANEB United States
- ENTX Israel
- Employees
- ANEB N/A
- ENTX N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANEB Health Care
- ENTX Health Care
- Exchange
- ANEB Nasdaq
- ENTX Nasdaq
- Market Cap
- ANEB 102.7M
- ENTX 86.3M
- IPO Year
- ANEB 2021
- ENTX 2018
- Fundamental
- Price
- ANEB $2.60
- ENTX $1.94
- Analyst Decision
- ANEB Buy
- ENTX Strong Buy
- Analyst Count
- ANEB 2
- ENTX 1
- Target Price
- ANEB $8.00
- ENTX $10.00
- AVG Volume (30 Days)
- ANEB 142.0K
- ENTX 290.3K
- Earning Date
- ANEB 09-24-2025
- ENTX 08-08-2025
- Dividend Yield
- ANEB N/A
- ENTX N/A
- EPS Growth
- ANEB N/A
- ENTX N/A
- EPS
- ANEB N/A
- ENTX N/A
- Revenue
- ANEB N/A
- ENTX $166,000.00
- Revenue This Year
- ANEB N/A
- ENTX N/A
- Revenue Next Year
- ANEB N/A
- ENTX N/A
- P/E Ratio
- ANEB N/A
- ENTX N/A
- Revenue Growth
- ANEB N/A
- ENTX 191.23
- 52 Week Low
- ANEB $0.80
- ENTX $1.50
- 52 Week High
- ANEB $3.42
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- ANEB 57.46
- ENTX 49.96
- Support Level
- ANEB $2.22
- ENTX $1.80
- Resistance Level
- ANEB $2.69
- ENTX $2.14
- Average True Range (ATR)
- ANEB 0.20
- ENTX 0.10
- MACD
- ANEB -0.04
- ENTX 0.00
- Stochastic Oscillator
- ANEB 65.52
- ENTX 48.00
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.